NewsBenzingaGilead Sciences Reports Phase 3 IDEAL Success For Livdelzi In PBC, With 75.4% Achieving ALP Normalization At Week 52 Vs 16.1% Placebo; Serious Adverse Events 3.1% Livdelzi Vs 12.9% Placebo; None Related To Drug Gilead Sciences Reports Phase 3 IDEAL Success For Livdelzi In PBC, With 75.4% Achieving ALP Normalization At Week 52 Vs 16.1% Placebo; Serious Adverse Events 3.1% Livdelzi Vs 12.9% Placebo; None Related To Drug Benzinga 2026.11.05 15:05 (GMT+0) Open on Benzinga Other news Canaccord Genuity Maintains Buy on Belite Bio, Raises Price Target to $314 Applied Optoelectronics Stock Sinks Amid AI Outlook Fears Canaccord Genuity Maintains Buy on Enovix, Lowers Price Target to $2.5 Canaccord Genuity Maintains Buy on Intuitive Machines, Lowers Price Target to $38 'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report Canaccord Genuity Maintains Buy on Nektar Therapeutics, Lowers Price Target to $149
'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report